Related Experiment Video
Updated: Aug 20, 2026
Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
Published on: June 3, 2022
Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein
Stacy M Cowherd1, Virginia A Espina, Emmanuel F Petricoin
1Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
Despite recent advances in breast cancer therapy, women with similar types of breast cancers may respond very differently to standard treatments. The emerging field of clinical proteomics has the potential to revolutionize breast cancer therapy. The ultimate goal of clinical proteomics is to characterize information flow through protein cascades for individual patients. After the protein networks have been elucidated, drug therapies may be specially designed for each patient. The following review describes the proteomic technologies of laser-capture microdissection (LCM) and reverse-phase protein arrays (RPPAs). These technologies allow scientists to analyze relative abundances of key cellular signaling proteins from pure cell populations. Cell survival and apoptotic protein pathways are currently being monitored with LCM and RPPAs at the National Institutes of Health, in phase II clinical trials of metastatic breast and ovarian cancers. Ultimately, proteomics will become an integral component of tracking and managing individualized breast cancer therapy.
Insights
Clinical proteomics offers personalized breast cancer therapy by analyzing protein pathways. Technologies like laser-capture microdissection and reverse-phase protein arrays enable tailored drug treatments for individual patients.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Breast cancer treatment response varies significantly among patients, even with similar cancer types.
- Clinical proteomics aims to understand individual protein signaling for personalized medicine.
- Current therapies lack the precision to account for individual patient variability.
Purpose of the Study:
- To review proteomic technologies for analyzing protein expression in breast cancer.
- To highlight the potential of proteomics in revolutionizing individualized cancer therapy.
- To discuss the application of specific proteomic tools in ongoing clinical trials.
Main Methods:
- Laser-capture microdissection (LCM) for isolating pure cell populations.
- Reverse-phase protein arrays (RPPAs) for quantifying protein abundances.
- Analysis of cell survival and apoptotic protein pathways.
Main Results:
- LCM and RPPAs enable the analysis of key signaling proteins from specific cell populations.
- These technologies are being utilized in phase II clinical trials for metastatic breast and ovarian cancers.
- Monitoring protein pathways provides insights into treatment response.
Conclusions:
- Proteomics holds significant potential to transform breast cancer treatment strategies.
- Individualized drug therapies can be designed based on elucidated protein networks.
- Proteomics will be integral to managing and tracking personalized breast cancer therapy.
